JP2007223910A - 抗炎症剤 - Google Patents
抗炎症剤 Download PDFInfo
- Publication number
- JP2007223910A JP2007223910A JP2006043869A JP2006043869A JP2007223910A JP 2007223910 A JP2007223910 A JP 2007223910A JP 2006043869 A JP2006043869 A JP 2006043869A JP 2006043869 A JP2006043869 A JP 2006043869A JP 2007223910 A JP2007223910 A JP 2007223910A
- Authority
- JP
- Japan
- Prior art keywords
- inflammatory
- lactoperoxidase
- weight
- peroxidase
- degradation product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002260 anti-inflammatory agent Substances 0.000 title claims abstract description 15
- 229940121363 anti-inflammatory agent Drugs 0.000 title claims abstract description 15
- 102000003992 Peroxidases Human genes 0.000 claims abstract description 34
- 108040007629 peroxidase activity proteins Proteins 0.000 claims abstract description 31
- 239000007857 degradation product Substances 0.000 claims abstract description 28
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 23
- 235000013361 beverage Nutrition 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 21
- 230000002757 inflammatory effect Effects 0.000 abstract description 17
- 102000004127 Cytokines Human genes 0.000 abstract description 16
- 108090000695 Cytokines Proteins 0.000 abstract description 16
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000001575 pathological effect Effects 0.000 abstract description 4
- 108091005804 Peptidases Proteins 0.000 abstract description 3
- 108090000631 Trypsin Proteins 0.000 abstract description 3
- 102000004142 Trypsin Human genes 0.000 abstract description 3
- 239000012588 trypsin Substances 0.000 abstract description 3
- 239000004365 Protease Substances 0.000 abstract description 2
- 230000000593 degrading effect Effects 0.000 abstract description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 47
- 102000045576 Lactoperoxidases Human genes 0.000 description 47
- 229940057428 lactoperoxidase Drugs 0.000 description 47
- 102000004890 Interleukin-8 Human genes 0.000 description 16
- 108090001007 Interleukin-8 Proteins 0.000 description 16
- 229940096397 interleukin-8 Drugs 0.000 description 14
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 14
- 235000013336 milk Nutrition 0.000 description 12
- 239000008267 milk Substances 0.000 description 12
- 210000004080 milk Anatomy 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000009471 action Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 235000020124 milk-based beverage Nutrition 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000013351 cheese Nutrition 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108700020962 Peroxidase Proteins 0.000 description 3
- 235000015895 biscuits Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000021995 interleukin-8 production Effects 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 230000007234 antiinflammatory process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 101710106940 Iron oxidase Proteins 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- ZCZCOXLLICTZAH-UHFFFAOYSA-N hypothiocyanous acid Chemical compound OSC#N ZCZCOXLLICTZAH-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
【解決手段】パーオキシダーゼ及び/又はパーオキシダーゼをトリプシン等のプロテアーゼで分解した分解物を有効成分とする、過剰な炎症性サイトカインの産生を抑制し、この炎症性サイトカインの過剰産生により引き起こされる各種病態を予防又は改善する抗炎症剤、及びパーオキシダーゼ及び/又はその分解物を配合した抗炎症用飲食品。
【選択図】なし
Description
実施例1で得られたラクトパーオキシダーゼ及び実施例2で得られたラクトパーオキシダーゼ分解物について、炎症性サイトカインIL-8の産生抑制作用を調べた。すなわち、小腸上皮細胞様の特徴を示すヒト結腸腺癌細胞株Caco-2を、24穴マイクロタイタープレート内において10%ウシ胎児血清を含有するダルベッコ変法基礎培地(DMEM)で2週間培養した後、過酸化水素(終濃度2mM)と実施例1で取得したラクトパーオキシダーゼ(終濃度5,10,50,100,250,500μg/ml)を添加した。さらに、24時間培養した後、培養上清を回収し、上清中に含まれるIL-8濃度をELISA法で測定した。その結果、ラクトパーオキシダーゼ濃度50μg/ml以上で、IL-8濃度の有意な低下が認められ、ラクトパーオキシダーゼにIL-8 産生抑制作用が確認された。また、実施例2で得られたラクトパーオキシダーゼ分解物(終濃度10,50,100,250μg/ml)についても同様に実験を行ったところ、50μg/ml以上の濃度でIL-8濃度の有意な低下がみられ、ラクトパーオキシダーゼ分解物にIL-8 産生抑制作用が確認された。さらに、実施例1で得られたラクトパーオキシダーゼを75℃、3分間で加熱処理した加熱物(終濃度250μg/ml)においても同様に実験したところ、IL-8濃度の有意な低下がみられ、加熱処理したラクトパーオキシダーゼにもIL-8 産生抑制作用が確認された。
実施例1で得られたラクトパーオキシダーゼ及び実施例2で得られたラクトパーオキシダーゼ分解物について、炎症性サイトカインIL-8のmRNA発現を抑制する作用を調べた。すなわち、小腸上皮細胞様の特徴を示すヒト結腸腺癌細胞株Caco-2を、24穴マイクロタイタープレート内において10%ウシ胎児血清を含有するダルベッコ変法基礎培地(DMEM)で2週間培養した後、過酸化水素(終濃度2mM)と実施例1で取得したラクトパーオキシダーゼ(終濃度5,50,100,250,500μg/ml)を添加した。さらに、4時間培養した後にCaco-2細胞を回収し、RNAを常法により回収し、cDNA合成を行ってRT-PCR法でmRNA発現量を定量した。その結果、過酸化水素によって誘導されるIL-8のmRNA発現量が、ラクトパーオキシダーゼ濃度50μg/ml以上で有意に低下した。すなわち、ラクトパーオキシダーゼに、酸化ストレスによって誘導されるIL-8の mRNA発現を抑制する作用が確認された。また、実施例2で得られたラクトパーオキシダーゼ分解物(終濃度5,50,100,250,500μg/ml)についても同様に実験を行ったところ、50μg/ml以上の濃度でIL-8mRNA発現量の有意な低下がみられ、ラクトパーオキシダーゼ分解物にIL-8 mRNA発現抑制作用が確認された。さらに、実施例1で得られたラクトパーオキシダーゼを75℃、3分間で加熱処理した加熱物(終濃度250μg/ml)においても同様に実験したところ、IL-8 mRNA発現量の有意な低下がみられ、ラクトパーオキシダーゼ加熱物にIL-8 mRNA発現抑制作用が確認された。
実施例1で得られたラクトパーオキシダーゼ100mgに、含水結晶ぶどう糖 93.4g、炭酸カルシウム5g、シュガーエステル1g、香料0.5gを加え、混和した後、タブレット状に打錠して、本発明の抗炎症剤を製造した。
実施例1で得られたラクトパーオキシダーゼを、1 l当たり1gとなるように生乳に添加し、均質圧力120kg/cm2でホモゲナイズした後、 75℃で15秒間加熱殺菌して、本発明の抗炎症用乳飲料を製造した。
実施例2で得られたラクトパーオキシダーゼ分解物を、 1 l当たり1gとなるように生乳に添加し、均質圧力120kg/cm2でホモゲナイズした後、 75℃で15秒間加熱殺菌して、本発明の抗炎症用乳飲料を製造した。
実施例1で得られたラクトパーオキシダーゼ40gを、乳酸でpH3.2に調整した脱イオン水50 lに溶解した後、砂糖1kg、香料10gを溶解して、90℃で15秒間加熱殺菌を行った。これを50 mlずつ蓋付きガラスビンに密封充填し、本発明の抗炎症用飲料を製造した。
実施例1で得られたラクトパーオキシダーゼ0.005重量%、小麦粉50.0重量%、砂糖20.0重量%、食塩0.5重量%、マーガリン12.5重量%、卵12.1重量%、水3.7重量%、炭酸水素ナトリウム0.1重量%、重炭酸アンモニウム 0.2重量%、炭酸カルシウム0.5重量%の割合で原料を混合し、ドウを作成して成型した後、焙焼して、本発明の抗炎症用ビスケットを製造した。
実施例1で得られたラクトパーオキシダーゼ0.0005重量%、果糖20.0重量%、グラニュー糖15.0重量%、水飴5.0重量%、寒天1.0重量%、香料0.11重量%、カルシウム0.1重量%、水58.39重量%の割合で原料を混合した後、容器に充填し、加熱滅菌して、本発明の抗炎症用ゼリーを製造した。
実施例1で得られたラクトパーオキシダーゼ0.005重量%、ゴーダチーズ43.0重量%、チェダーチーズ43.5重量%、クエン酸ナトリウム2.0重量%、乳由来カルシウム1.0重量%、水10.5重量%の割合で原料を混合した後、85℃で乳化して、本発明の抗炎症用プロセスチーズを製造した。
実施例1で得られたラクトパーオキシダーゼ0.001重量%、脱脂乳75.61重量%、乳清タンパク質濃縮物2.36重量%、乳糖13.86重量%、ミネラル混合物0.32重量%、水溶性ビタミン混合物0.32重量%、脂溶性ビタミンを含む脂肪7.53重量%の割合で原料を混合し、本発明の抗炎症用乳児用調製粉乳を製造した。
実施例1で得られたラクトパーオキシダーゼ0.001重量%、大豆粕12.0重量%、脱脂粉乳14.0重量%、大豆油4.0重量%、コーン油2.0重量%、パーム油28.0重量%、トウモロコシ澱粉15.0重量%、小麦粉9.0重量%、ふすま2.0重量%、ビタミン混合物9.0重量%、ミネラル混合物2.0重量%、セルロース 3.0重量%の割合で原料を混合して、本発明の抗炎症用イヌ飼育用飼料(ドッグフード)を製造した。
Claims (2)
- パーオキシダーゼ及び/又はその分解物を有効成分とする抗炎症剤。
- パーオキシダーゼ及び/又はその分解物を配合した抗炎症用飲食品、医薬又は飼料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006043869A JP2007223910A (ja) | 2006-02-21 | 2006-02-21 | 抗炎症剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006043869A JP2007223910A (ja) | 2006-02-21 | 2006-02-21 | 抗炎症剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007223910A true JP2007223910A (ja) | 2007-09-06 |
Family
ID=38546050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006043869A Pending JP2007223910A (ja) | 2006-02-21 | 2006-02-21 | 抗炎症剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2007223910A (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004073733A1 (ja) * | 2003-02-24 | 2004-09-02 | Morinaga Milk Industry Co., Ltd. | インターロイキン−6産生抑制剤 |
JP2005060321A (ja) * | 2003-08-15 | 2005-03-10 | Snow Brand Milk Prod Co Ltd | 骨形成促進剤 |
-
2006
- 2006-02-21 JP JP2006043869A patent/JP2007223910A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004073733A1 (ja) * | 2003-02-24 | 2004-09-02 | Morinaga Milk Industry Co., Ltd. | インターロイキン−6産生抑制剤 |
JP2005060321A (ja) * | 2003-08-15 | 2005-03-10 | Snow Brand Milk Prod Co Ltd | 骨形成促進剤 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4536341B2 (ja) | 骨形成促進剤 | |
US5932259A (en) | Bone reinforcing agent and foods and drinks product containing the same | |
US7939099B2 (en) | Sustained improver of muscular fatigue | |
JP2001158736A (ja) | 骨関節疾患の予防及び改善剤 | |
US20080206226A1 (en) | Agent for promoting osteogenesis and/or inhibiting bone resorption | |
JP4740531B2 (ja) | 骨吸収抑制剤 | |
JP2009215301A (ja) | プロテアーゼ阻害剤 | |
JP2004238320A (ja) | 骨吸収抑制剤 | |
JPWO2009057281A1 (ja) | 骨芽細胞分化促進及び破骨細胞分化抑制用食品素材 | |
JP5188523B2 (ja) | 骨形成促進及び骨吸収抑制剤 | |
JP2007223910A (ja) | 抗炎症剤 | |
JP4208799B2 (ja) | 炎症性サイトカイン産生抑制剤 | |
JP4868700B2 (ja) | プロテアーゼ阻害剤 | |
JP5120971B2 (ja) | 骨吸収抑制剤 | |
JP4028177B2 (ja) | 血圧降下剤 | |
WO2022039215A1 (ja) | 筋肉の分解抑制剤 | |
JP5379884B2 (ja) | 骨吸収抑制剤 | |
JP4659405B2 (ja) | 骨形成促進剤 | |
AU2014226865B2 (en) | Anti-inflammatory agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090129 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20110706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110817 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111017 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120119 |